Teva Pharmaceuticals (NYSE:TEVA) is the world's largest generic-drug maker. Somewhat ironically for a company that specializes in generics, its business is struggling at the moment as its own blockbuster patent-protected drug, Copaxone, just lost its patent protection in the U.S.
Two teams of competitive pharmaceutical companies with generics businesses are launching their own version of Copaxone as Teva's patent expires. One team consists of Mylan (NASDAQ:MYL) and India's Natco, while the other is driven by Momenta Pharmaceuticals (NASDAQ:MNTA) and Novartis (NYSE:NVS).
Those partnerships are willing to take on Teva with their own versions of Copaxone despite Teva's own incredibly strong generics business. That's a clear sign that they believe there's still some profit to be had from the drug, even as its patent-granted exclusivity expires.
Still, Teva's core generics business remains profitable, and it was that generics business that first made Teva an attractive pick for the real-money Inflation-Protected Income Growth portfolio. In the slideshow below, portfolio manager Chuck Saletta reviews Teva in light of the Copaxone patent loss and determines whether he'd be willing to buy more, hold on, or part ways with the generic pharmaceutical giant.
To follow the iPIG portfolio as buy and sell decisions are made, watch Chuck's article feed by clicking here. To join The Motley Fool's free discussion board dedicated to the iPIG portfolio, click here. To see the iPIG portfolio's online tracking spreadsheet, click here.
Chuck Saletta owns shares of Teva Pharmaceutical Industries. The Motley Fool recommends Momenta Pharmaceuticals and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.